Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026)
Talphera (TLPH) posted Other Non-Current Liabilities of $1.7 million for Q2 2026, up 48.57% on a QoQ basis from $1.2 million in Q1 2026, and up 125.69% year-over-year from $759000.0 in Q2 2025.
Analysis
Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Talphera has reported Other Non-Current Liabilities for 17 years, with the latest figure at $1.7 million in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 125.69% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 125.69% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 123.94% from the prior year.
- Other Non-Current Liabilities was $1.7 million for Q2 2026 at Talphera, up from $1.2 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $84.6 million in Q1 2022, with the low at $759000.0 in Q2 2025.
- Average Other Non-Current Liabilities over 5 years is $6.6 million, with a median of $1.8 million recorded in 2023.
- The largest YoY upside for Other Non-Current Liabilities was 46648.62% in 2022 against a maximum downside of 99.04% in 2022.
- Over 5 years, Other Non-Current Liabilities stood at $7.1 million in 2022, then plunged by 74.95% to $1.8 million in 2023, then slumped by 40.33% to $1.1 million in 2024, then soared by 123.94% to $2.4 million in 2025, then slipped by 27.9% to $1.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.7 million (Q2 2026), $1.2 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 759,000.00 |
| Mar 31, 2025 | 880,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.38 Mn |
| Jun 30, 2023 | 3.09 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 7.10 Mn |
| Sep 30, 2022 | 827,000.00 |
| Jun 30, 2022 | 849,000.00 |
| Mar 31, 2022 | 84.62 Mn |
| Dec 31, 2021 | 85.29 Mn |
| Sep 30, 2021 | 85.98 Mn |